Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Psyence Biomed Exports Psilocybin to Australia and Prepares Phase IIb Trial
Details : PEX010 (psilocybin) reacts agonistically with 5-HT2A receptors to produce a hallucinatory effect due to induced frontal hyper-frontality, investigated for the treatment of adjustment disorders.
Brand Name : PEX010
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 24, 2024
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?